Icariin ameliorates metabolic syndrome-induced benign prostatic hyperplasia in rats
- 4 November 2021
- journal article
- research article
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 29 (14) , 20370-20378
Abstract
Metabolic syndrome (MetS) is an immense health issue that causes serious complications in aging males including BPH. Icariin (ICA) is a flavonol glycoside that exerts a plethora of pharmacological effects. The present investigation tested the potential of ICA to ameliorate benign prostatic hyperplasia (BPH) induced by MetS in rats. Animals were allocated to 5 groups in which the first and second groups were kept on water and regular food pellets. MetS was induced in the third, fourth, and fifth groups by keeping the animals on high fructose and salt diets for twelve consecutive weeks. These groups were given vehicle, ICA (25 mg/kg), and ICA (50 mg/kg), respectively. MetS was confirmed by an increase in rats’ weight, accumulation of visceral fat, insulin resistance, and dyslipidemia. This was accompanied by manifestation of BPH including increased prostate weight, prostate index, and histopathological alterations. Treating the animals with both doses of ICA significantly ameliorated the increase in weight and index of the prostate as well as altered prostate histopathology. In addition, ICA significantly decreased cyclin D1 expression, upregulated Bax, and downregulated Bcl2 mRNA expression. ICA prevented lipid peroxidation, reduced glutathione depletion, and catalase exhaustion, which further lowered markers of prostate inflammation such as interleukin-6 and tumor necrosis factor-α. Moreover, ICA prevented the decrease in prostate content of phosphorylated 5′-adenosine monophosphate (AMP)-activated protein kinase (pAMPK). In conclusion, ICA protects against MetS-induced BPH. This is due to its antiproliferative, proapoptotic, antioxidant, and anti-inflammatory activities as well as the activation of AMPK.Keywords
All Related Versions
Funding Information
- Deanship of Scientific Research, King Saud University
This publication has 53 references indexed in Scilit:
- Developmental, Cellular and Molecular Biology of Benign Prostatic HyperplasiaDifferentiation, 2011
- Icariin induces apoptosis in mouse MLTC-10 Leydig tumor cells through activation of the mitochondrial pathway and down-regulation of the expression of piwil4International Journal of Oncology, 2011
- Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008BJU International, 2011
- Counter-modulation of fatty acid-induced pro-inflammatory nuclear factor κB signalling in rat skeletal muscle cells by AMP-activated protein kinaseBiochemical Journal, 2011
- In vivoandin vitroanti-inflammatory effects of a novel derivative of icariinImmunopharmacology and Immunotoxicology, 2010
- Oxidative stress and metabolic syndromeLife Sciences, 2009
- The Perfect Storm: Obesity, Adipocyte Dysfunction, and Metabolic ConsequencesClinical Chemistry, 2008
- A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cellsEuropean Journal of Pharmacology, 2007
- Vasorelaxant Effects of Icariin on Isolated Canine Coronary ArteryJournal of Cardiovascular Pharmacology, 2007
- The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygenBiochemical and Biophysical Research Communications, 1972